Lowe on MANF. Academia moving forward based on interest in Manf. which we have moved forward on licensing the IP. Focus develeoping orphan indications, and also as a curative for parkinsons. Developed efficacy and toxicology in the eye. Other studies underway, IND, protein production, tox and efficacy and potentially diabetes. He remains very confident in MANF. Perparing manf for submission to fda in optomology.